is...(working and trading)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GFME Delaware Info. 11/30/2011
Same. No Change. LW
RE: GFME George Foreman Enterprises, Inc. file number 2617538
Wednesday, November 30, 2011 10:07 AM
From:"DOSDOC WEB (DOS)"
To:"Larry Walker"
They’re authorized 25,000,000 shares of common stock at .01 par value and 5,959,509 shares of Preferred stock at .01 par value.
Thank you for contacting our office, have a nice day…...
Thank You,
Information Center
State of Delaware ,
Div. of Corporations
401 Federal Street, Ste # 4
Dover, De 19901
Phone 302-739-3073
www.corp.delaware.gov
TDGI TA Info for 11/30/2011
Same. No Change. LW
Target Development Group
TDGI: From T/A Talked to Andrea.
OS 477,995,139 --11/30/2011
RS 140,325,186 --11/30/2011
Float 337,669,953
:Transfer Agent:
Standard Registrar and Transfer Co. Inc.
12528 South 1840 E.
Draper, UT 84020
Your answer is in this file under
g) Graham Financial Services, Inc.
http://www.otcmarkets.com/financialReportViewer?symbol=TDGI&id=65891
The Company issued an additional 11.5-million shares to Graham Financial during the current reporting period against the debt-conversion structure. The shares issued to Graham Financial Services, Inc. were not restricted.
My thoughts:
Paying down debt is a good thing. If I was going to buy a company like TDGI I would not want them to have a lot of debt.
Go TDGI!
LW
SeaWorld Dives Into Home Entertainment
http://www.prnewswire.com/news-releases/connecting-to-the-sea-from-your-sofa--seaworld-dives-into-home-entertainment-134675093.html
Launches First Consumer DVD at Retail: "Turtle: The Incredible Journey"
SEAWORLD PARKS & ENTERTAINMENT TURTLE: THE INCREDIBLE JOURNEY SeaWorld Parks & Entertainment announced today its expansion into the sale of home entertainment products in retail outlets with the release of "Turtle: The Incredible Journey." The DVD and Blu-ray of the film is now available through retailers and on-line sellers nationwide. The film is available to consumers on Netflix, Amazon, Blockbuster and Best Buy Web sites as well as in Walmart and Kroger retail stores. Orlando, Fla. SeaWorld Parks & Entertainment. (PRNewsFoto/SeaWorld Parks & Entertainment) ORLANDO, FL UNITED STATES
ORLANDO, Fla., Nov. 29, 2011 /PRNewswire/ -- SeaWorld Parks & Entertainment announced today its expansion into the sale of home entertainment products in retail outlets with the release of "Turtle: The Incredible Journey." The DVD and Blu-ray of the film is now available through retailers and on-line sellers nationwide. The film is available to consumers on Netflix, Amazon, Blockbuster and Best Buy Web sites as well as in Walmart and Kroger retail stores.
(Photo: http://photos.prnewswire.com/prnh/20111129/FL13708 )
SeaWorld Parks & Entertainment develops entertainment products that connect people to nature and animals, and the company's new product line will bring to life such extraordinary stories for a home audience.
Other DVDs set for retail release in 2012 include "Saving a Species," the Emmy Award-winning series (individual titles and special collector sets) that tells the story of endangered animals and conservation projects. Each title in the series tells the story of a different species, from penguins and manatees to gorillas and elephants, educating viewers about these animals' unique characteristics and struggles for survival. The home entertainment line also will feature DVDs of live theatrical productions seen in the SeaWorld parks, giving fans the opportunity to view these popular shows as often as they like.
Details on "Turtle: The Incredible Journey" release:
This award-winning, stunning documentary follows the life and migration of a loggerhead turtle from hatching to maturity and a return to its original Florida nesting grounds. The loggerhead turtle, a threatened species, has one of the longest and most difficult migrations of any marine animal: Newly hatched sea turtles make their way from the beach into the ocean, and then begin a voyage that can span the entire Atlantic Ocean, only to return decades later to that same beach. The film follows the loggerhead turtle on an adventure of more than 9,000 miles.
In addition to the feature film, bonus materials on both the DVD and Blu-ray releases include interviews with director Nick Stringer and narrator Miranda Richardson, and a look behind-the-scenes at SeaWorld's wildlife rescue program. Turtles are among the dozens of species that benefit from the rescue program, which has aided 20,000 mammals, birds, reptiles and fish since its inception.
For information about the film and retail locations, visit www.turtle-film.com.
The 10 parks of SeaWorld Parks & Entertainment inspire 23 million guests a year to celebrate and conserve the natural world. Through up-close animal encounters, educational attractions and innovative entertainment, each of those guests leaves with a heightened sensitivity to the world around them and an awareness of the plight of animals in the wild.
The company also announced this year the formation of SeaWorld Pictures.
SeaWorld Parks & Entertainment offers rich content for consumer products and entertainment including one of the world's largest zoological collections, world-class shows and rides, high-quality themed attractions, a successful rescue and rehabilitation program for animals in need, and support for conservation and wildlife research worldwide. The parks care for more than 60,000 animals including 200 endangered or threatened species.
SOURCE SeaWorld Parks & Entertainment
Back to top
RELATED LINKS
http://www.turtle-film.com
http://photos.prnewswire.com/medias/switch.do?prefix=/appnb&page=/getStoryRemapDetails.do&prnid=20111129%252fFL13708&action=details
According to the Breast Cancer Organization of the USA, it is estimated that more than 260,000 new cases of breast cancer were diagnosed last year. The dreaded disease has rightfully never slipped from the spotlight, but has garnered stronger attention again with the latest news about Avastin®. By targeting drug-resistant cancer strains and outpacing Etoposide, Sunshine Biopharma's Adva-27 is right in the mix with other anti-cancer drugs in development. Just as Herceptin® revolutionized HER2 therapies for breast cancer - and generated nearly $7 billion in 2010 sales alone - Sunshine is looking to do the same with its Top2 drug in the future.
Go SBFM!
LW
Volume is looking better today. Might be some covering going on.
Go SBFM!
LW
Symptoms Vs. Problems: AtheroNova (OTC:AHRO) 'Gets' Cholesterol, MRK & BMY Don't.
http://www.smallcapnetwork.com/Symptoms-Vs-Problems-AtheroNova-OTC-AHRO-Gets-Cholesterol-MRK-BMY-Dont/s/via/10/article/view/p/mid/1/id/77/
It can be somewhat discouraging to investors when a home remedy of lemon juice, honey, or spinach takes on drugs created by the likes of Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY), and the home remedy actually holds its own in the fight. Fortunately AtheroNova Inc. (OTC:AHRO) is in a position to redeem the pharmaceutical industry.
The battleground is the war against cholesterol, or more specifically, the negative health effects of too much so-called bad cholesterol (LDL). Merck unveiled Zocor to treat the condition, and Bristol-Myers Squibb launched Pravachol; there are about thirteen major anti-cholesterol dugs out there right now. As time passes though, the pros of these treatments - mostly statins - are starting to diminish, while the 'cons' are starting to swell.
It's a trend that the likes of Merck and Bristol-Myers Squibb should be worried about, since $40 billion worth of annual anti-cholesterol drug sales are at stake. It's a trend AtheroNova Inc. is reveling in though, as it's not missing the boat its bigger pharma brothers missed.
As it turns out, lowering your cholesterol doesn't necessarily decrease your odds of heart attack or cardiovascular health risks... once the root cause of those risks sets in. That root cause is plaque-covered arteries. Pravachol, Zocor, and all of their statin peers have been shown to remove cholesterol from the blood, but they generally don't undo atherosclerosis - the covering of artery wills with hard, fatty deposits - unless dosed in dangerously-high quantities. AtheroNova's lead drug candidate is an actual treatment for the dangerous condition.
The AHRO biotechnology is founded on bile salts rather than on a statin molecule designed to inhibit HMG-CoA reductase. Statins crimp the amount of enzyme that ultimately leads to the creation of mevalonate - the molecule created right before 'cholesterol' is formed in the liver. The problem is, by inhibiting HMG-CoA reductase, the drug's mechanism has also been observed to cause other problems, including the inhibited production of so-called 'good cholesterol (HDL). Bile salts occur naturally in the body, in that they're reduced by the liver and stored in the gall bladder, for the purpose of digesting some fats and to prevent certain toxins from being stored in the body's fat. In many ways, bile salts are a body's garbage men.
It's not exactly a new idea for the health-savvy. Bile salts have been used as OTC health supplements to treat psoriasis, septicemia, and constipation just to name a few.
And, people at heart disease risk who are also health supplement consumers are no stranger to putting heart-related ailments on the list of targets. Everything from fish oil also vera gel to garlic to lemon juice have been used with the intent of eating away at arterial plaque. AtheroNova Inc. is taking a similar 'organic' approach, but building its drug directly based on the mechanism that the body itself uses to fight artery plaque as best it can. That's where Bristol-Myers Squibb, Merck, and others fall short.
It's still a long road to pave for AHRO owners, but that's biotech. Any milestones met in the meantime as the drug makes its way through the development gauntlet are likely to be rewarded.
AtheroNova is developing products that will regress atherosclerotic plaque deposits. The plaque on artery walls that results in heart attacks and strokes will be dissolved, fully or partially, by these natural compounds, if all goes well. For that to happen, approval must be secured from the Food and Drug Administration after successful research, development and testing. AtheroNova (AHRO) has the management team in place that can make that happen through experience, not hope. Investors should take note. This has been demonstrated by the successful results of a recent test at the University of California Los Angeles,
http://www.smallcapnetwork.com/AtheroNova-has-Management-Team-needed-for-Success-AHRO-PFE-AZN/s/via/3420/article/view/p/mid/1/id/416/
LW
AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
Findings Reported at the American Heart Association Scientific Sessions Conference
IRVINE, Calif., Nov. 22, 2011 /PRNewswire via COMTEX/ -- AtheroNova Inc. (AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced the recent presentation by Diana Shih, Ph.D., Associate Professor of Medicine, Division of Cardiology at the David Geffen School of Medicine at UCLA, at the 2011 American Heart Association (AHA) Scientific Sessions in Orlando, Florida. Dr. Shih's presentation included information on research sponsored by the Company which demonstrated that dietary supplementation of AHRO-001 resulted in a 95% reduction in arterial plaque formation at the innominate artery when compared to the control group.
The study results also revealed significant reduction in plasma cholesterol and dietary cholesterol absorption in the test subjects that received HDCA. HDCA supplementation also improved HDL function as measured by cholesterol efflux assay. These factors indicate multiple methods of action for an anti-atherogenic effect, suggesting a clear potential for new anti-atherosclerotic therapy.
"We are extremely pleased with the results of the UCLA study and want to thank Dr. Shih for all of her efforts on this presentation," said Thomas W. Gardner, CEO of AtheroNova. "The data from this study confirms and enhances our initial research and understanding of the compounds. As a result, we are moving forward with the preparation of an Investigative New Drug (IND) application with the Food and Drug Administration (FDA) for our atherosclerotic plaque regression compounds, in addition to, preparations for entry into Phase I human trials during 2012."
"Presenting such positive data to an audience of industry peers at AHA validates the potential of AtheroNova's compounds," Gardner concluded.
Dr. Shih's presentation can be viewed on the American Heart Association's website at .
About AtheroNova AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis, obesity and lipomas.
Forward-Looking Statements Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding the value of Dr. Nicholls' appointment to AtheroNova's scientific advisory board, and the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE AtheroNova Inc.
Copyright (C) 2011 PR Newswire. All rights reserved
AHRO Interest is picking up. Can't wait until Monday!
LW
GFME Delaware Info. Same. No Change. LW
From: "Gorman Lori A (DOS)"
To: "'Larry Walker'"
Thank you for your inquiry. George Foreman Enterprises, Inc. currently has 25,000,000 shares of common stock and 5,959,509 shares of preferred stock authorized, both at .01 par value.
Thank you for contacting the Delaware Division of Corporations.
Information Center
Division of Corporations
401 Federal Street Suite 4
Dover, Delaware 19901
Phone: 302-739-3073
Fax: 302-739-3812
www.corp.delaware.gov
Sunshine Biopharma Inc. (SBFM) is on the OTCQB.
http://www.otcmarkets.com/stock/SBFM/company-info
Business Description
Sunshine Biopharma is a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead anti-cancer compound, Adva-27a, is currently in late stage preclinical studies.
Website: http://www.sunshinebiopharma.com
Phone: 514-764-9698
Email: info@sunshinebiopharma.com
Excellent Company we have found here.
Go SBFM!
LW
News from Oct 12th, 2011
A drug which could fill a major gap in the treatment of aggressive cancers has been developed by Sunshine Biopharma (OTCBB: SBFM), a development stage pharmaceutical company focused on drugs for the treatment of various forms of cancer.
The company’s lead compound, Adva-27a, has been shown to be remarkably effective in dealing with the Topoisomerase II (Top2) gene, which is responsible for the production of Top2, associated with breast, prostate, colon, lung, stomach and ovarian cancer.
Read more: http://www.beaconequity.com/sunshine-biopharma-inc-sbfm-to-fill-gap-in-cancer-treatment-2011-10-12/#ixzz1alNaa0zV
Great things are happening here!
Go SBFM!
LW
Starting to look like our time is nearby.
Go GFME!
LW
GFME Delaware A/S info for 11/02/2011
Same. No Change. LW
The authorized shares are:
COMMON = 25,000,000 at .01 par value
PREFERRED = 5,959,509 at .01 par value
Thank you for your inquiry.
Information Center
Delaware Division of Corporations
401 Federal Street, Suite 4
Dover, DE 19901
TEL: (302)739-3073 option 2
FAX: (302)739-3812
www.corp.delaware.gov
TDGI TA Info For 11/02/2011
Same. No Change. LW
Target Development Group
TDGI: From T/A Talked to Andrea.
OS 477,995,139 --11/02/2011
RS 140,325,186 --11/02/2011
Float 337,669,953
:Transfer Agent:
Standard Registrar and Transfer Co. Inc.
12528 South 1840 E.
Draper, UT 84020
"All's Faire In Love" New York Premeire
http://www.gettyimages.com/Search/Search.aspx?EventId=130393525&EditorialProduct=Entertainment
See EP and Fred!
Go TDGI!
LW
TDGI TA Info for 10/25/2011
Same. No Change. LW
Target Development Group
TDGI: From T/A Talked to Andrea.
OS 477,995,139 --10/25/2011
RS 140,325,186 --10/25/2011
Float 337,669,953
:Transfer Agent:
Standard Registrar and Transfer Co. Inc.
12528 South 1840 E.
Draper, UT 84020
Asalto al cine (The Cinema Hold-Up)
Hannover House, the entertainment division of Target Development Group, Inc., (TDGI.PK), has set February 17, 2012 as the U.S. Theatrical launch date for the acclaimed Mexican drama, "Asalto Al Cine" ("The Cinema Hold Up").
About the Film: http://www.mfah.org/films/asalto-al-cine/
Negus, Chale, Sapo, and Chata are four typical, bored, apathetic teenagers from one of the most dangerous areas in the Cuauhtémoc borough of Mexico’s Colonia Guerrero. But unlike most teens, they have decided to do something about their situation: hold up a megaplex cinema. First-time filmmaker Iria Gómez Concheiro moves the film forward beautifully—from establishing the aimless day-to-day lives of the main characters, through the planning of the heist, to the actual crime—with confident and fluid camera movement and direction. The narrative builds assuredly as the film moves from observing the self-destructive tendencies of the protagonists and the world that offers them scant opportunities to the execution of the crime that ironically gives some meaning to their lives. The Cinema Hold-Up is an entertaining critique of Mexico’s failing social system that perfectly fuses an engaging heist film with a tragic, coming-of-age slacker story.
Born in Mexico City, Iria Gómez Concheiro attended the Centro de Capacitación Cinematográfica, and also studied cinematography with Vittorio Storaro at the Centro Sperimentale di Cinematografia in Rome. After completing her studies, she formed the production company Ciudad Cinema, with whom she made several film projects in Mexico and abroad. Her short film Dime lo que sientes won several awards at national and international festivals in France, Italy, Russia, Argentina, Egypt, and Israel, including the Ariel for best fiction short from the Mexican Academy of Film Arts and Sciences. The Cinema Hold-Up is her first feature film.
Go TDGI!
LW
Turtle Dvd's go on sale Nov 15th.
Go TDGI!
LW
"We're very honored to already be working with Michael and Patriot Pictures," said Eric Parkinson, C.E.O. of Hannover House and Target Development Group, Inc. "We see great synergies between our companies and benefits to expanding our relationship for upcoming titles. We are working together to determine the best structure for such a venture, and feel that we are closing in on a solid plan."
Hannover House is a full-service entertainment distribution company, with direct relationships with all major theatrical exhibition circuits. The company also operates its own home video division, and on selected titles, has partnered with 20th Century Fox Home Video, Inc.
Go TDGI!
LW
“All’s Faire in Love” as Regal’s first studio exclusive release venture. EP explained that Regal is the nation’s largest theatre circuit, with over 6,775 screens, and that their film and marketing teams have agreed to provide maximum marketing and promotional support for the film due to this being their first, exclusive venture.
Go TDGI!
LW
Regal Entertainment Group and Hannover House Launch National Campaign for "All's Faire In Love"
High Profile Campaign Designed to Generate Over 300 Million Consumer Impressions
Hannover House, the entertainment division of Target Development Group, Inc. (TDGI.PK) has launched the national support campaign and promotions with Regal Entertainment Group for the October 28 theatrical release of "All's Faire In Love," starring Christina Ricci.
Go TDGI!
LW
In The Spotlight
All's Faire In Love on www.REGMovies.com
The multi-faceted marketing, advertising and publicity campaign for the film includes home-page visibility with Regal's official website, www.REGMovies.com, and extensive support with advertising, publicity and in-theatre promotions.
Go TDGI!
LW
TDGI : OTC Market Tier OTC Pink Current
Target Development Group, Inc. is the owner of entertainment media distributor Truman Press, Inc., d/b/a "Hannover House," a well-known and respected publisher of books and distributor of film and video properties, established in 1993 and operating continuously since. Hannover House has a library of over 100 properties, with more than 70 titles in current release to the book, DVD, television or international markets. The company's senior executives are proven top professionals in the film distribution and banking industries, and the company's release philosophy fits into a market niche with limited competition.
Romance has a renaissance!
Christina Ricci stars as a performer who leaves her investment banking opportunities to join her cousin at a renaissance faire to blossom on stage in the film ALL’S FAIRE IN LOVE, in theaters October 28th! Hannover House has unleashed the film’s one-sheet and images, check ‘em out below!..
http://www.ramascreen.com/alls-faire-in-love-starring-christina-ricci-and-cedric-the-entertainer-in-theaters-october-28th-images-and-poster
Go TDGI!
LW
COOK COUNTY Release Date: November 11, 2011
In this coming-of-age story, the absentee father (Xander Berkeley) of an alienated teenage boy (Ryan Donowho) returns home to a small town in East Texas, to discover a household of crystal meth addicts. The father, Sonny, and his teenage son, Abe, struggle to reconnect and stay clean while sharing their house with an abusive uncle (Anson Mount), who goes by the nickname "Bump". The uncle's meth-fueled rage increasingly threatens the safety of the entire family, especially the uncle's six year old daughter, Deandra. In the end, in order to save Deandra and himself from Bump's spiraling behavior, Abe is left with only one option; and Sonny, the redemptive father, must sacrifice his life to give his son the future he deserves.
Director: David Pomes
Writer: David Pomes
Stars: Anson Mount, Xander Berkeley and Ryan Donowho
Go TDGI!
LW
Plus the AS was lowered. What company does that in pennyland?
Authorized Shares: 700,000,000
(Reduced by 93% from 10 billion to 700 million on 4/7/10)
You can verify that here: https://wyobiz.wy.gov/Business/FilingDetails.aspx?FilingNum=2009-000565408
Outstanding Shares: 477,995,139
Transfer Agent
Standard Registrar and Transfer Co., Inc.
12528 South 1840 E.
Draper, UT 84020
Phone: (801) 571-8844
Transfer Agent is NOT gagged.
Call them and they'll tell you the Outstanding Shares and float.
Go TDGI!
LW
ALL’S FAIRE IN LOVE is directed by Scott Marshall and stars Christina Ricci, Owen Benjamin, Ann-Margaret, Matthew Lillard and Cedric the Entertainer.
Synopsis: Set in the world of Renaissance Faires – unique societies of actors, singers, glass-blowers, ale merchants, sword-smiths, and other crafts people dedicated to preserving the living memory of the golden age of the European Renaissance – “All’s Faire in Love”… is a film reminiscent of such successful films as “Shakespeare in Love” and “The Princess Bride.” The tale begins when college football star Will (Owen Benjamin) arrives at “All’s Faire in Love… Renaissance Faire” to work off his class non-attendance obligation to Prof. Shockworthy (Cedric the Entertainer) by joining the rag-tag peasant Greenbriar Theater Troupe.
The same is true for Kate (Christina Ricci), a performer who left her investment banking opportunities to join her cousin Jo (Louise Griffiths) to blossom on stage and in Will’s heart. Will and Kate get the chance to prove themselves when the Faire’s chief benefactress create the ultimate competition to determine who will be a “Royal” and who a “Common Peasant” threatening to hand over the Troupe’s most coveted Shakespearean stage at the Faire – to a the treacherous and devious Troupe of Royals lead by Rank (Chris Wylde). Will and Kate must overcome all manner of opposition and treachery to prove their worth, win the day, and perhaps… together …fall in love.
Go TDGI!
LW
STATUS OF “TOYS IN THE ATTIC” – Parkinson reported that the current activities for the English adaptation of the Czech film, “TOYS IN THE ATTIC” were progressing as scheduled, and that three major stars had committed to participating in this venture, on behalf of Eurocine Films. A detailed, public announcement of the cast and project status would be withheld until completion of the recording sessions.
Go TDGI!
LW
SURRENDER OF OFFICER SHARES – Fred Shefte presented a performance-based incentive plan and motion for restructuring of the Company’s Common Stock share structure to provide incentives for key management members to achieve certain corporate governance targets. As structured, Eric Parkinson would immediately surrender fifteen-million (15,000,000) shares of the Company’s Common Stock and Fred Shefte would surrender five-million (5,000,000) shares of the Company’s Common Stock back to the Company as treasury shares. These surrendered shares would be taken back from the managers’ existing and respective personal holdings. In order to preserve each manager’s voting position, a pro-rata number of Series A Preferred Shares would be issued. However, the voluntary surrender of the above, 20-million shares of Common Stock would be permanent unless the Company met pre-determined goals set by the Board, including the maintenance of fully reporting status and the consistent achievement of targeted results. The shares could be reissued, in full or in part, no sooner than the filing of the second quarter results for the period ending June 30, 2012, upon approval of the Board of Directors. If the Board determined that adequate performance levels had been achieved at that time, or at any time thereafter, the shares could be reissued and the management could also be eligible to receive modest, cash bonuses predicated upon the Company’s cash position at that time. The motion was brought to vote and passed unanimously. Based on the current, open-market trading price, the value of the Common Stock Shares surrendered by Eric Parkinson, C.E.O. is $396,000 and the value of the shares surrendered by Fred Shefte, President is $132,000.
Go TDGI!
LW
SCREEN ACTOR’S GUILD SIGNATORY STATUS – Fred Shefte proposed to the Board the terms of the documents and agreements covering “SAG Signatory Producer Status” for the company, a move required for the current re-voicing activities with the film, “Toys in the Attic” and the engagement of three, major motion picture stars. A motion was proposed, seconded and unanimously passed by the Board to execute the Screen Actors Guild Producer Signatory agreements for “Toys in the Attic” as drafted.
Go TDGI!
LW
Based upon the enthusiasm being expressed by Regal for the exclusive launch of “All’s Faire in Love,” Parkinson felt that the film was well-positioned to exceed expectations. He also felt that this agreement with Regal could be followed up with other feature releases, and that other Hannover releases (even those not released under an exclusive agreement) could benefit from the closer relationship between the companies.
Go TDGI!
LW
"There's quite a bit more in the works that will be announced over the next two weeks," said Eric Parkinson, C.E.O. of Hannover House and Target Development Group, Inc. "We're honored and excited to be partnered with Regal Entertainment Group, Inc., on their first theatrical exclusive, and hope to draw a lot of attention to this film."
Regal Entertainment Group operates over 6,700 screens in more than 550 locations in America under the marquee brands of Regal Cinemas, Edwards Theatres and United Artists Theatres.
"All's Faire In Love" is a romantic comedy starring Christina Ricci
Go TDGI!
LW
All's Faire In Love in the Spotlight on the Regal Movie site at www.REGMovies.com
The multi-faceted marketing, advertising and publicity campaign for the film includes home-page visibility with Regal's official website, www.REGMovies.com, and extensive support with advertising, publicity and in-theatre promotions.
Go TDGI!
LW
Plus Regal has 268,145 "Likes" on Facebook. They must be doing something right.
Go TDGI!
LW